Bio-based Transformation of Organic Solvents for Achieving Carbon Neutrality

Nitto Denko Corporation (hereinafter referred to as "Nitto") is pleased to announce that it has signed a contract with Crysalis Biosciences Inc., (US, CEO: Sanket Gandhi, hereafter "Crysalis") to jointly develop plant-derived acetonitrile as a bio-based solvent, as well as to invest in Crysalis, as part of its efforts to achieve carbon neutrality.

Efforts to reduce environmental impact in oligonucleotide contract manufacturing

Nitto recognizes the bio-based transformation of acetonitrile, a major organic solvent used in the synthesis and purification process of oligonucleotide intermediates in its contract manufacturing business, as an important initiative towards achieving carbon neutrality by reducing consumption of petrochemical resources, and is committed to realizing this initiative.

Crysalis possesses innovative bio-refinery technology that converts plant-derived raw materials into various chemicals. The process uses microbial fermentation combined with catalytic upgrading technology. Ultimately, this bioprocess enables a pathway to low carbon intensity organic solvents with high environmental value.

Going forward, Nitto will work towards the bio-based transformation of acetonitrile using Crysalis' innovative bio-refinery technology as a pioneering effort in pharmaceutical manufacturing, and strive to reduce environmental impact throughout the entire supply chain.

Future developments

Through this strategic collaboration, established by our business capital alliance, both companies will further develop technologies that contribute to reducing environmental impact by combining Nitto's polymer membrane separation technology with Crysalis' bio-refinery technology.

Nitto will also strengthen marketing efforts within the United States, the main market, viewing bio-refining as a promising growth field, and will work towards expanding into new business areas by creating niche top products.

About Crysalis Biosciences Inc.,

Crysalis is a bioprocess technology demonstration, manufacturing, and licensing company. Using our portfolio of Intellectual Property, we design, build, and operate turnkey biochemical plants to manufacture the next generation of low Carbon Intensity (CI) biofuels and biochemicals. For more information about Crysalis, please visit https://www.crysalisbio.com.

Contact Us

For any inquiries about this press release.

1-800-755-8273

Business Hours (EST)
8:00 a.m.-5:30 p.m.(Except for Sat, Sun, and Holidays)

E-mail

Notice
Here is the information at the release day. This information may be different from the information at other medias. Please be forewarned.